DV
Dividend Vision

ARWR — Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (ARWR)

Total return is -97.0% over the past 32.7 years, 2976.4 points behind SPY at 2879.4%. Its deepest 1-year drawdown was 24.6%.

Arrowhead Pharmaceuticals is a healthcare equity stock focused on the development of RNA interference (RNAi) therapeutics and other innovative drug treatments. The company does not currently pay dividends, making it unsuitable for income-focused investors seeking regular distributions. This security appeals primarily to growth-oriented investors interested in exposure to the biotechnology and pharmaceutical sector, rather than those prioritizing dividend yield.

ARWR key facts

Asset type
Stock
Asset class
Equity
Inception date
12/16/1993
Distribution frequency
None
Last close
$86.64
Market cap
$12,055,952,384
Average volume
818000.0
Beta
1.294
Payout ratio
0.0
Forward P/E
111.1111
EPS
$-2.28